Add like
Add dislike
Add to saved papers

Long-term outcome and patterns of failure in patients with advanced head and neck cancer.

PURPOSE: To access the long-time outcome and patterns of failure in patients with advanced head and neck squamous cell carcinoma (HNSCC).

METHODS AND MATERIALS: Between 1992 and 2005 127 patients (median age 55 years, UICC stage III n=6, stage IV n=121) with primarily inoperable, advanced HNSCC were treated with definite platinum-based radiochemotherapy (median dose 66.4 Gy). Analysed end-points were overall survival (OS), disease-free survival (DFS), loco-regional progression-free survival (LPFS), development of distant metastases (DM), prognostic factors and causes of death.

RESULTS: The mean follow-up time was 34 months (range, 3-156 months), the 3-, 5- and 10-year OS rates were 39%, 28% and 14%, respectively. The median OS was 23 months. Forty-seven patients achieved a complete remission and 78 patients a partial remission. The median LPFS was 17 months, the 3-, 5- and 10-year LPFS rates were 41%, 33% and 30%, respectively. The LPFS was dependent on the nodal stage (p=0.029). The median DFS was 11 months (range, 2-156 months), the 3-, 5- and 10-year DFS rates were 30%, 24% and 22%, respectively. Prognostic factors in univariate analyses were alcohol abuse (n=102, p=0.015), complete remission (n=47, p<0.001), local recurrence (n=71, p<0.001), development of DM (n=45, p<0.001; median OS 16 months) and borderline significance in nodal stage N2 versus N3 (p=0.06). Median OS was 26 months with lung metastases (n=17). Nodal stage was a predictive factor for the development of DM (p=0.025). Cause of death was most commonly tumor progression.

CONCLUSIONS: In stage IV HNSCC long-term survival is rare and DM is a significant predictor for mortality. If patients developed DM, lung metastases had the most favourable prognosis, so intensified palliative treatment might be justified in DM limited to the lungs.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app